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Abstract
Background:  The use of low-molecular-weight, non-peptidic molecules that disrupt the
interaction between the p53 tumor suppressor and its negative regulator MDM2 has provided a
promising alternative for the treatment of different types of cancer. Among these compounds,
RITA (reactivation of p53 and induction of tumor cell apoptosis) has been shown to be effective in
the selective induction of apoptosis, and this effect is due to its binding to the p53 tumor
suppressor. Since biological systems are highly dynamic and MDM2 may bind to different regions
of p53, new alternatives should be explored. On this basis, the computational "blind docking"
approach was employed in this study to see whether RITA would bind to MDM2.
Results: It was observed that RITA binds to the MDM2 p53 transactivation domain-binding cleft.
Thus, RITA can be used as a lead compound for designing improved "multi-target" drugs. This novel
strategy could provide enormous benefits to enable effective anti-cancer strategies.
Conclusion: This study has demonstrated that a single molecule can target at least two different
proteins related to the same disease.
Background
The p53 tumor suppressor is one of the principal media-
tors of cell-cycle arrest and the activation of apoptosis in
response to a broad array of cellular injuries [1-4]. In nor-
mal unstressed cells, p53 is regulated by a feedback loop
with the negative regulator protein MDM2 (murine dou-
ble-minute clone 2, referred to as human double-minute
clone 2, HDM2, in humans) [1,2,5]. A well-known mech-
anism for the loss of wild-type p53 activity in cancer cells
is the overexpression of MDM2, which leads to constitu-
tive inhibition of p53 and thus allows the tumor cells to
escape from p53-induced apoptosis [6].
Recent studies have shown that rescue of p53 function by
disruption of the p53-MDM2 interaction may be a prom-
ising strategy for developing new anti-cancer drugs [7-9].
To date, different research groups have reported diverse
peptidic and non-peptidic molecules that bind at the
MDM2-p53 transactivation domain-binding cleft [10-16].
In all cases, these molecules bind to MDM2 and block the
p53-MDM2 interaction. In contrast, Issaeva et al. reported
the small molecule RITA (reactivation of p53 and induc-
tion of tumor cell apoptosis, Figure 1), which binds to
p53 and targets it for proteasomal degradation [17]. The
most interesting feature of RITA was its ability to increase
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the p53-dependent antitumor effect in vivo by inducing a
conformational change in p53, which prevented MDM2
binding. In principle, targeting MDM2 or p53 should be
sufficient to induce apoptosis effectively in cancer cells.
However, considering that biological systems are not
static, and that proteins present a certain degree of plastic-
ity due to the pre-existence of conformational popula-
tions, the traditional single-drug-single-target approach
should be replaced by the single-drug-multiple-target
approach. By employing the latter, we can obtain benefits
from the "promiscuous" behavior of a potential drug by
targeting different proteins with a single molecule [18].
Thus, the possibility that RITA binds to both p53 and
MDM2 makes it an attractive lead compound for further
development of potent and effective anti-cancer drugs.
In the present study the computational "blind docking"
approach [19] is used in order to determine the possibility
of RITA binding and its preferential binding sites. It was
found not only that RITA can bind efficiently to the
MDM2 p53 transactivation domain-binding cleft, but
also that is highly specific for its binding site. The results
of this study support the effectiveness of the "multi-target"
approach in anti-cancer drug design.
Results and discussion
The objective of this study was to demonstrate that RITA,
a drug originally found to bind the p53 tumor suppressor,
is also able to bind at the MDM2-p53 transactivation
domain-binding cleft, which increases its effectiveness
and makes it a lead compound for further anti-cancer drug
design efforts.
By using the "blind docking" approach, it was found that
RITA preferentially binds to the hydrophobic MDM2 p53
transactivation domain-binding cleft. RITA could also
bind to other faces of the protein, but this occurred with
low frequency. In this case, 81 independent runs out of
100 placed RITA in the MDM2 p53 transactivation
domain-binding cleft. The orientation with the most pop-
ulated cluster is shown in Figure 2. Moreover, "fine dock-
ing" focused on the binding cleft showed that 93 out of
100 independent runs accommodated RITA in the same
orientation as that observed in the most populated cluster
obtained through the "blind docking" procedure. These
results imply that RITA is highly specific for the MDM2-
p53 transactivation domain-binding cleft. It is also notice-
able that RITA covers most of the cleft surface, accommo-
dating horizontally to the cavity and then behaving as a
"cap", avoiding p53 to bind to MDM2.
As observed in Figure 3, RITA interacts with the MDM2 as
follows: one of the hydroxymethyl-thiophene moieties in
the molecule makes contact with residues G58, I61, M62
and Y67, while the other interacts with residues L54, H96,
I99, Y100 and I103. Finally, the furan ring makes the only
contact with V93. Most of the interactions are favored by
van der Waals and hydrophobic interactions. This finding
is consistent with the structural composition of both the
MDM2-p53 transactivation domain-binding cleft and the
thiophene and furan rings, which present large hydropho-
bic regions.
The calculated binding free energy shows a moderate
affinity for MDM2 (Table 1). The stabilizing energy of the
complex comes principally from the van der Waals and
hydrophobic terms. Subsequently, some hydrogen bonds
can be formed between the hydroxyl moieties of the RITA
backbone nitrogen, oxygen and hydrogen atoms. How-
ever, it is not possible at this stage to determine which res-
idues play an important role in forming such interactions,
due to the lack of flexibility of MDM2 during the docking
experiments.
As mentioned in the introduction, RITA was previously
found to bind to the p53 tumor suppressor, which
induces its accumulation in tumor cells and leads to selec-
tive apoptosis [17]. It was hypothesized that RITA
behaved as an allosteric modulator, inducing conforma-
tional changes in p53 and preventing it from binding
MDM2 but preserving its functional role. Unfortunately,
the full structure of the p53 tumor suppressor is not avail-
able, which impedes global screening of the best RITA
binding site. Nevertheless, there is enough experimental
evidence showing that RITA binds to p53. This work dem-
onstrates that RITA could also bind to the MDM2-p53
transactivation domain-binding cleft.
An important point to consider is that it was shown exper-
imentally that RITA does not bind to MDM2 [17]. Never-
theless it was found in this study that the base structure of
the compound (the 2,5-di-thiophen-2-yl-furan moiety)
was able to bind to the p53-binding cleft. Preliminary
docking studies on different NMR structures of MDM2
showed that RITA can actually bind to the same binding
cleft over different MDM2 conformations. This suggests
that RITA itself might not be a potent MDM2 inhibitor,
Chemical structure of RITA [2,5-bis(5-hydroxymethyl-2- thienyl)furan] Figure 1
Chemical structure of RITA [2,5-bis(5-hydroxymethyl-2-
thienyl)furan].Theoretical Biology and Medical Modelling 2005, 2:38 http://www.tbiomed.com/content/2/1/38
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but the binding affinity for both MDM2 and p53 might be
improved by modifying its structure. The apparent inabil-
ity of RITA to bind to MDM2 in experiments might be due
to the need for high concentrations of this compound to
attain effective inhibition. This possibility correlates well
with our docking simulations, in which the computed dis-
sociation constant of RITA binding to MDM2 is relatively
high.
The experimental Kd obtained for RITA binding to p53 is
1.5 nM, while the computed Kd of RITA binding to MDM2
is 22 µM. This means that RITA binds some ~15000 times
more tightly to p53 than to MDM2. Thus, to use RITA as
is would be problematic in principle, since much higher
concentrations would be necessary to target both p53 and
MDM2 efficiently. The physiological consequences are
obvious. On this basis, it is proposed in this study that
RITA could be markedly improved to increase its effective-
ness on MDM2, while retaining its effectiveness on p53.
Thus, structural modifications in RITA would alleviate the
lack of selectivity for MDM2, making it an effective multi-
target drug.
To visualize the approach presented here better, the fol-
lowing factors should be kept in mind: a) biomolecules
are not static entities but are constantly involved in
dynamic processes; b) MDM2 displays important confor-
mational transitions when binding to different fragments
of the N-terminal domain of p53 [20] and can interact
with the core domain of the latter [21,22]; c) p53 may
Orientation of the best ranked cluster obtained by using the "blind docking" procedure Figure 2
Orientation of the best ranked cluster obtained by using the "blind docking" procedure. RITA is rendered as van der Waals 
spheres and MDM2 as a surface.Theoretical Biology and Medical Modelling 2005, 2:38 http://www.tbiomed.com/content/2/1/38
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mutate in key residues, hindering RITA binding but not
altering its physiological role; d) as pointed by Van Regen-
mortel, the binding site should not be visualized without
considering the binding partner [23]; and e) as remarked
by Weaver and co-workers, a promiscuous drug candidate
is not a collection of different molecules acting in combi-
nation on different receptors implicated in the pathogen-
esis of a disease, but rather a single molecule capable of
binding to a range (albeit a limited range) of targets [24].
Thus, improved RITA derivatives could bind not only to
p53 but also to MDM2, which would increase or reinforce
its therapeutic effect. In other words, the "multi-target"
behavior observed by these compounds would compen-
sate their therapeutic deficiencies because of the dynamic
nature of the targets involved and the observed promiscu-
ity of MDM2 over p53. Thereby, RITA could serve as a lead
compound for designing improved, low-toxicity and
highly effective apoptosis inducers via p53 activation and
facilitating the effective inhibition of p53 ubiquitination
by MDM2. Its effectiveness would then be improved by its
action on multiple pathways related to the disease [18].
Currently, additional simulations are being carried out
that allow MDM2 to flex, in order to sample the confor-
mational space more thoroughly, and modifications of
the RITA structure are in course. These simulations will
help to determine the structural keys involved in the
molecular recognition mechanism, to modify the struc-
Perspective of the best raked cluster obtained through the "blind docking" procedure Figure 3
Perspective of the best raked cluster obtained through the "blind docking" procedure. RITA is shown as van der Waals 
spheres; residues G58, I61, M62 and Y67 are shown as blue surface; residues L54, H96, I99, Y100 and I103 are shown as lime 
surface; V93 is shown as red surface.Theoretical Biology and Medical Modelling 2005, 2:38 http://www.tbiomed.com/content/2/1/38
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ture of RITA and to improve the activity of a new family of
potent anti-cancer drugs.
Conclusion
The aim of the present study was to support the viability
of the multi-target approach in the design of anti-cancer
drugs. For this purpose, a recently described system, the
MDM2-p53 complex, was successfully used as a study
model.
"Blind" and "fine" docking simulations using the Auto-
Dock program revealed that RITA, a molecule originally
investigated for binding to the p53 tumor suppressor, can
also bind to the MDM2 p53 transactivation domain-bind-
ing cleft. As a multi-target drug acting on several proteins
related to the same disease, RITA could be more therapeu-
tically effective in the treatment of some types of cancer.
These findings open a new and exciting perspective for
effective cancer treatment with low-molecular-weight,
non-peptidic molecules.
Structural modifications of RITA may help not only to
increase the effectiveness of its binding to MDM2 and
p53, but also to elucidate the common structural features
of p53 and MDM2 in order to improve the anti-cancer
activity of a new family of RITA-derived drugs.
Materials and methods
Protein preparation
The X-ray structure of human MDM2 in complex with the
p53 transactivation domain was used in the present study
(PDB code: 1YCR). For docking purposes, the p53 frag-
ment was removed from the original PDB file. Hydrogen
atoms were added to the protein and the structure was
minimized by 500 steps using the conjugate gradient pro-
tocol and employing the CHARMM27 force field imple-
mented in NAMD 2.5 software [25]. Subsequently, non-
polar hydrogens were merged from the protein and Koll-
man united atom charges were assigned. Finally, the pro-
tein was equipped with fragmental volumes and solvation
parameters.
Ligand setup
The structure of RITA [2,5-bis(5-hydroxymethyl-2-
thienyl)furan] (Figure 1) was optimized at the AM1 sem-
iempirical level, and the Gasteiger-Marsili formalism [20]
was employed to derive the partial charges on the atoms.
The AUTOTORS utility, included in the latest version of
AutoDock (3.0.5) [26], was used to define the torsions of
RITA.
Molecular Docking
Docking simulations were carried out in two stages using
version 3.0.5 of the AutoDock program [27]. This pro-
gram is one of the most reliable docking tools available
today because it uses the efficient Lamarckian Genetic
algorithm and its scoring function comprises several
terms (van der Waals, coulomb potential electrostatics,
directional hydrogen bonding, a volume-based solvation
term and an estimation of the entropic cost of binding
through a weighted sum or torsional degrees of freedom).
In addition, the possible binding site need not be speci-
fied since the algorithm allows the entire surface of the
target to be searched efficiently.
The grid maps representing the protein were calculated
with the aid of AutoGrid, a utility of the AutoDock soft-
ware. Two different grid maps with different dimensions
were calculated for the protein. In the first stage, a cubic
box of 120 × 120 × 120 points, with a spacing of 0.35 Å
between the grid points and centered on the geometric
center of the protein, was calculated in order to carry out
the "blind docking" experiment. The dimensions of the
box were sufficient to cover the entire surface of MDM2.
In the second stage, a smaller box (50 × 50 × 50 points,
spacing 0.35 Å) was built centered on the most populated
binding site, using its geometric center as a reference. This
smaller box was employed for performing "fine docking"
on the most populated binding site found during the
"blind docking" stage. In both cases, docking simulations
were carried out using the Lamarckian Genetic Algorithm
with an initial population of 300 individuals, a maximum
number of 50,000,000 energy evaluations, a maximum
number of 50,000 generations, a translation step of 2 Å, a
quarternion step of 50° and a torsion step of 50°. For
each local search, the pseudo-Solis and Wets algorithm
was applied using a maximum number of 300 iterations.
Both the blind and refined docking simulations consisted
of 100 independent runs. Resulting orientations lying
within 2.0 Å in the RMSD were clustered together and
represented by the orientation with the most favorable
free energy of binding.
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